Survival of Patients Treated for Locally Advanced Cervical Cancer with Concomitant Radiochemotherapy and Followed at the Brazzaville University Hospital

Introduction:Globally, cervical cancer is the fourth leading cause of cancer death in women, with an estimated 661,021 new cases and 348,189 deaths in 2022, with the highest rates recorded in countries with a low sociodemographic index.In Congo, a real public health problem, it is the second cancer in women after breast cancer.The main objective of this study was to estimate the overall survival of patients treated for locally advanced cervical cancer with concomitant radiochemotherapy (CCR) and followed at the Brazzaville University Hospital. Methods:This was a retrospective study of locally advanced cervical cancers that received treatment with RCC and were followed at the Brazzaville University Hospital between 2015 and 2024.Survival was estimated using the Kaplan-Meier method.The study of prognostic factors was done using the Log-Rank test for the comparison between different classes of the same variable and the Cox model for multivariate analysis.Results: A total of 43 cases of cervical cancer that benefited from RCC were collected at the Brazzaville University Hospital between 2015 and 2024.The mean age was 56.7 13.8 years, with extremes of 31 and 84 years.Forty cases (93.2%) were discovered as a result of gynecological symptoms.Squamous cell carcinoma was found in 40 patients (93.02%).FIGO stage II was the most common (53.49%).All patients were treated with RCC and 8 (18.60%) received complementary brachytherapy.Twenty-two (51.16%) female patients died during the study period.The overall survival rate was 79.65% at 3 years and 51.6% at 5 years.The 3-and 5-year PFS were 67.11% and 36.74%,respectively.No significant prognostic factors were found in the cohort. Conclusion:The overall 5-year survival rate in cervical cancer patients treated with RCC in Brazzaville is relatively good.The results provide valuable information for research and policy development in the prevention and management of cervical cancer.Cervical cancer is the uncontrolled and uncontrolled proliferation of malignant cells developed at the expense of the subisthmic part of the uterus [1].Cervical cancer ranks fourth among women after breast, colorectal and lung cancers globally [2,3].It represents the fourth leading cause of cancer death in women, with an estimated 661,021 new cases and 348,189 deaths worldwide according to GLOBOCAN 2022, with the highest rates recorded in countries with a low sociodemographic index [3].In Central Africa, according to the same source, more than 4740 new cases of cervical cancer, resulting in 3391 (71.4%) deaths have been recorded.According to the International Federation of Gynecology and Obstetrics classification (FIGO 2018), the stages between IB3 and VIA are defined as locally advanced cervical cancer [4,5].For this group